Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 1:04 PM
Ignite Modification Date:
2025-12-24 @ 1:04 PM
NCT ID:
NCT00861861
Eligibility Criteria:
Inclusion Criteria:
* Patients with dyslipidemia as defined by any of the parameters:
* HDL-C \< 50 mg/dL
* LDL-C ≥ 140 mg/dL
* LDL-C ≥ 100 mg/dL and cholesterol-lowering treatment is necessary in accordance with the investigator's judgement
* Patients who passed three months or more after acute myocardial infarction
* Patients who passed one month or more after unstable angina
* Patients who passed one month or more after PCI
* Patients with written consent by their own volition after being provided sufficient explanation for the participation into this clinical trial
Exclusion Criteria:
* Patients with any allergy to pitavastatin or atorvastatin
* Patients with familial hypercholesterolemia
* Patients receiving pitavastatin
* Patients with severe hypertension
* Patients with renal disorders or undergoing dialysis
* Patients with hepatobiliary disorders
* Patients with hepatobiliary disorders
* Patients with family history of hypothyroidism or muscular dystrophy
* Patients with history of drug-induced hepatic disorder
* Drug abuser or dipsomaniac
* Patients with cardiogenic shock.
* Patients who hopes for pregnancy during this study
* Contraindications, Relative Contraindications, Absolute Contraindications for Coadministration and Relative Contraindications for Coadministration for pitavastatin or atorvastatin
* Patients who are ineligible in the opinion of the investigator
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
20 Years
Maximum Age:
85 Years
Study:
NCT00861861
Study Brief:
Protocol Section:
NCT00861861